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The current study investigates the structural and compositional changes of ocular basement membranes
(BMs) during long-term diabetes. By comparing retinal vascular BMs and the inner limiting membrane
(ILM) from diabetic and non-diabetic human eyes by light and transmission electron microscopy (TEM), a
massive, diabetes-related increase in the thickness of these BMswasdetected. The increase in ILM thickness
was conﬁrmedbyatomic forcemicroscopy (AFM)onnative ILMﬂat-mount preparations. AFMalsodetected
a diabetes-induced increase in ILM stiffness. The changes in BM morphology and biophysical properties
were accompanied by partial changes in the biochemical composition as shown by immunocytochemistry
andwestern blots: agrin,ﬁbronectin and tenascin underwent relative increases in concentration in diabetic
BMs as compared to non-diabetic BMs. Fibronectin and tenascin were particularly high in the BMs of
outliningmicrovascular aneurisms. The present data showed that retinal vascular BMs and the ILMundergo
morphological, biomechanical and compositional changes during long-term diabetes. The increase in
BM thickness not only resulted from an up-regulation of the standard BM proteins, but also from the
expression of diabetes-speciﬁc extracellular matrix proteins that are not normally found in retinal BMs.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
As of 2012, diabetes affects more than 300 million people
worldwide and its incidence and prevalence continues to increase
(Sherwin and Jastreboff, 2012). While there is existing medication
to successfully treat hyperglycemia and ketoacidosis, long term,
chronic conditions, like diabetic nephropathy, neuropathy, and
delayed wound healing are not well controlled. Diabetic retinop-
athy affects nearly 40% of individuals with type II diabetes, and 86%
of individuals with type I diabetes in the United States alone
(Cheung et al., 2010). Given its prevalence, it remains the leading: þ1 412 648 1441.
r Ltd. Open access under CC BY-NC-NDcause of preventable blindness in individuals under the age of 50
(Frank, 2004; Fong et al., 2004; Kempen et al., 2004).
One of the hallmarks of long-term diabetes is a massive thick-
eningof basementmembranes (BMs) that has beenparticularlywell
documented for retinal vascular BMs (Ashton,1974; Roy et al., 2010;
Osterby, 1990; Tsilibary, 2003). BMs are thin sheets of extracellular
matrix that are important for structural integrityof epithelia,muscle
ﬁbers, blood vessels and peripheral nerves (Yurchenco and Patton,
2009; Halfter et al., 2013a). Major BM proteins include type IV
collagen, laminin, nidogen, and several members of the proteogly-
can family, including perlecan, agrin, and collagen XVIII. Pro-
teoglycans are the prime water-binding constituents in the highly
hydrated BMs (Erickson and Couchman, 2000; Timpl and Brown,
1996). Abnormalities in the regulation of the expression of these
BM components and in the expression of growth factors in the
diabetic eye may play an important role in BM thickening and dis-
ease development in diabetic retinopathy (King, 2001; Tsilibary,
2003). It has been postulated that BM thickening may be linked to license.
Table 1
Diabetic eyes. Overview of basic eye donor characteristics for the diabetic patients.
# Age Gender Race Cause of death Med history
1 38 m w MI IDDM; Type Ix30y
2 52 m w Peritonitis IDDM; type IIx17y
3 54 f w ICH IDDM; Type IIx30y
4 61 f w MI IDDM; type IIx15y
5 62 m w MI IDDM; type IIx25y
6 79 m w MI NIDDM; type IIx10y
7 80 f w CA NIDDM; type IIx42;
IDDMx10y
8 81 m w MI IDDM; type IIx10y
9 83 m b CHF NIDDM; type IIx15y
10 83 f w Accident NIDDM; type IIx10y
11 83 m w MI IDDM; type IIx20y
12 85 f w CHF IDDM type IIx10y
13 87 m w MI NIDDM; type IIx3y
Type II or I: diabetes type II; or I.
x30y: duration of the diabetic condition for 30 years.
CVA ¼ Cerebrovascular accident.
ICH ¼ Intracerebral hemorrhage.
MI ¼ Myocardial infarction.
MVA ¼ motor vehicle accident.
CA ¼ cancer.
CHF ¼ congestive heart failure.
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in hyperglycemia (Degenhardt et al., 1998; King, 2001; Stitt et al.,
1997; Zhang et al., 2009), excessive cross-linking and a decreased
rate of BM protein degradation, and an up-regulation of BM protein
synthesis (Kuiper et al., 2008; Roy et al., 2010).
It is still unresolved why and how BMs become thicker and why
this thickening leads to chronic disease conditions associated with
diabetes, like diabetic retinopathy. It is reasonable to postulate that
excessively thick BMs impede the passage of oxygen, proteins and
immune cells and thereby contribute to hypoxia-induced uncon-
trolled angiogenesis in the retina and vitreous, to peripheral nerve
damage, and to delayed wound healing (Kuiper et al., 2008). BM
thickening may also result in a loss of vascular elasticity, thereby
contributing to elevated blood pressure (Curtis et al., 2009; Durham
and Herman, 2011; Zatz and Brenner, 1986).
Previous investigations have shown that human BMs undergo
morphological, biophysical and compositional changes with
advancing age (Candiello et al., 2010). In a comparative study of
these changes in diabetic and non-diabetic ocular BMs using
transmission electron microscopy we show that the thickness of
BMs from diabetic patients is massively increased compared to age-
matched non-diabetic patients. TEM uses sample preparations
requiring dehydration that normally leads to shrinkage of tissues.
To this end, we also investigated the age-related morphological
changes of the ILM in fully hydrated conditions using Atomic Force
Microscopy (AFM). AFM also provided data on diabetes-induced
biomechanical changes. To explore the compositional changes in
BMs between age-matched diabetic and non-diabetic patients, we
used immunocytochemistry and western blotting.
The present study shows that the BMs of the human eye un-
dergo diabetes-dependent alterations that include an increase in
thickness and stiffness and in diabetes-related changes in its
biochemical composition. We propose that BMs from other tissues
undergo similar changes.
2. Methods
2.1. Human eyes and antibodies
Adult human eyes were obtained from CORE, the “Center of
Organ Recovery and Education” of the University of Pittsburgh.The use of the human eyes was approved by the Institutional
Review Board of the University of Pittsburgh under the IRB
Exempt Protocol number #0312072. The clinical data for the
diabetic eyes are listed in Table 1. The clinical data for the non-
diabetic eyes was previously listed (Halfter et al., 2013b). Poly-
clonal antisera to collagen IV, laminin-1 were obtained from
Rockland Immunochemicals (Gilbertsville, PA), Sigma (St. Louis,
MO), Invitrogen (Carlsbad, CA), and Santa Cruz Biotechnology
(Santa Cruz, CA). The polyclonal rabbit anti-human agrin anti-
serum was raised against a fusion protein from the N-terminal
part of human agrin (Cotman et al., 2000). A monoclonal antibody
to cellular ﬁbronectin (Mab 1940) was purchased from Millipore,
Temecula CA. Monoclonal antibodies to tenascin C (Mab RR1) and
to the 7S domain of collagen IV a3/4/5 (Mab J3-2; SundarRaj and
Wilson, 1982) were kindly provided by Dr. Ruth Chiquet-
Ehrisman, Friedrich Miescher Institute Basel, Switzerland and
Dr. Nirmala SundarRaj, University of Pittsburgh. SytoxGreen
(Molecular Probes, Eugene, OR) was used as a nuclear counter
stain.
2.2. Histology
For immunocytochemistry, fetal eyes or adult retinal samples
were ﬁxed in 4% paraformaldehyde and processed for cryostat-
sectioning as described (Candiello et al., 2010). The sections were
mounted in 90% glycerol and examined with an epiﬂuorescence or
a confocal microscope (Flowview, Olympus). For transmission
electron microscopy, samples from the dorso-central retina were
ﬁxed in 2.5% glutaraldehyde, 2.5% paraformaldehyde overnight. The
samples were osmicated and embedded in EPON according to
standard procedures. Thin sections were examined by a JEOL
electron microscope at 25,000. TEM measurements of ILM
thickness are based on the analysis of 27 pairs of non-diabetic and
11 diabetic human eyes. The eyes were enucleated from donors less
than 30 h after expiration with expiration-enucleation intervals of
approximately 10 h. Retinal samples were taken from both eyes,
and two thin sections per retina sample were surveyed at 25,000.
At least twenty ILMmeasurements per retinal samplewere taken at
random, and the average value standard deviation was calculated
for the pairs of eyes.
2.3. ILM and vascular BM preparation and western blotting
ILMs and vascular BMs sheets were prepared by incubating
segments of adult human retina overnight in 2% Triton-X-100 in
water. The detergent-insoluble BMs were transferred with a Pas-
teur pipette under a dissecting microscope and under dark-ﬁeld
illumination into new Triton-X-100 and 1% deoxycholate
(Duhamel et al., 1983; Candiello et al., 2010; Halfter et al., 2013b).
The transfer was repeated 3-times. The washed BMs were pelleted
by centrifugation at 10,000 rpm. To facilitate the solubilization of
the ILM proteins for SDS PAGE, the ILM pellets were incubated
with 100 mL of each 0.1 mU/ml ﬂavium, heparinum, heparitinase 1
and chondroitinase ABC for 1 h (Seikagaku Corporation, Japan).
The deglycosylation step of the sample was omitted for the
detection of the GAG-glycosylated agrin. 10 SDS sample buffer
and solid urea is added to a ﬁnal concentration of 1 and 8 M,
respectively. The samples were boiled for 10 min, centrifuged and
loaded onto 3.5e15% SDS gradient gels. The blotting was per-
formed using a semi-dry blotting device (Biorad, Hercules, CA).
The blots were blocked in 2% dry milk followed by primary anti-
bodies at a dilution of 1:1000 for 4 h. Alkaline-phophatase-labeled
antibodies (1:1000 for 4 h; Jackson ImmunoResearch) followed by
NBT/BCIP (Roche, Indianapolis, IN) staining were used to visualize
the protein in the blots.
Fig. 1. Ultrastructure of diabetic and non-diabetic human retinal vascular BMs. Representative TEM micrographs show cross sections of similar-sized retinal capillaries from
a 62-year old diabetic (A) and a 74-year old non-diabetic patient (B). While the lumen of both vessels (L) are similar in size, the associated vascular BM is much wider in the
diabetic eye (A; black bar) than in the non-diabetic eye (white bars; B). Dark-ﬁeld image showing the two types of BM sheets isolated from adult human retina as they
appear under a dissecting microscope: to the left, a sheet of vascular BMs, to the right, the ILM. Both BM sheets were isolated from the foveal area of a diabetic retina. The
foveal avascular zone (FAZ, arrow) is clearly visible in the vascular BM sheet (C). The foveal area is also recognizable in the ILM by its darker appearance (arrow C). An SEM
(D) and a TEM image (E) of isolated vascular BMs sheets showed clean extracellular matrix tubes that are not contaminated by cellular debris. Scale bar: A, B, E: 2 mm; D:
10 mm.
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ILM ﬂat mounts for AFM probing were prepared in the
following way: glass slides were coated with 10 mg/ml polylysine
(P-1524; Sigma). The coated area of the slide was encircled with a
PAP-Pen (Research Products International, Mt. Prospect, IL) to
contain the droplet of PBS that holds the BM samples. Segments of
ILMs were transferred into the PBS droplet, excessive PBS was
removed, and the slides were centrifuged at 1000 rpm for 5 min
to ﬁrmly attach the ILMs to the poly-lysine-coated slides
(Candiello et al., 2010). The immobilized BMs were washed 3
times in PBS and immuno-stained for laminin or collagen IV for
better visualization. The imaging and thickness measurements
were done by an MFP-3D AFM (Asylum Research, Santa Barbara,
CA) mounted on top of the Olympus IX-71 ﬂuorescence micro-
scope (Olympus, Tokyo, Japan) as described previously (Candiello
et al., 2007, 2010). For all experiments, 100 mm long silicon-
nitride triangular cantilevers with pyramidal tips were used
(Veeco, Inc, Santa Barbara, CA) that have a nominal spring con-
stant of w0.8 N/m. The spring constant was individually calcu-
lated for each cantilever prior to experimentation using the
thermal ﬂuctuation method (Hutter and Bechhoefer, 1993). For
thickness measurements 25 measurements were taken at 4
randomly selected locations. Average values with standard de-
viation were calculated. Statistical analysis was performed using
Student’s T-test.
All nanostiffness measurements were done using ARTIDIS AFM
system (Nanosurf AG, Liestal, Switzerland) as described before
(Henrich et al., 2012). Brieﬂy, we used triangular cantilever with a
nominal spring constant of 0.081 N/m (HYDRA6V-200WG, App-
Nano, Santa Clara, USA) and nominal tip radius of 6 nm. In total,
we measured 12 samples (6 from diabetic and 6 from non-
diabetic patients) and each sample on at least 10 different areas.
Stiffness was measured in Force Spectroscopy mode using a force
of 1.8 nN and over an area of 25 mm2 where for each 100 force
curves were collected. Using ARTIDIS analysis software, we
calculated the dynamic elastic modulus based on the Oliver and
Pharr theory.3. Results
3.1. Diabetes-related morphological changes of the retinal vascular
BMs
Diabetes-related changes of retinal vascular BMs have tradi-
tionally been recorded by using transmission electron microscopy
(TEM) imaging of human retinal samples (Ashton, 1974; Osterby,
1990; Roy et al., 2010; Tsilibary, 2003). Consistent with earlier re-
sults, we found that of the BM walls of similar-caliber capillaries of
diabetic eyes were consistently thicker than from similar aged non-
diabetic eyes (Fig. 1A, B). Problematic in quantifying the thickness
differences was the selection of capillaries to be compared and the
fact that the capillaries were not consistently sectioned perpen-
dicularly to their long axis. We therefore isolated the vascular BM
sheets from adult human diabetic and non-diabetic eyes (Fig. 1C).
SEM and TEM of the isolated BMs showed that the isolated BM
sheets are not contaminated with cellular debris or organelles
(Fig. 1D, E). The vascular BM sheets were prepared as ﬂat-mounts
and stained with anti-collagen IV for whole mount evaluation
and capillary diameter measurements (Fig. 2A, B). We assumed that
the thin capillary BM tubes in diabetic and non-diabetic eyes have a
similar-diameter inner lumen that allows the passage of individual
red blood cells and that an increase in the outer diameter of
capillary BM tubes of diabetic relative to similar aged non-diabetic
eyes is predominantly due in an increase in the thickness of the
BMs outlining the vessels. An increase in the diameter of a capillary
BM tubes was, therefore, considered a measure for an increase in
the thickness of the vascular BMs. For consistency, we exclusively
measured the caliber of the capillary tubes that outline the foveal
avascular zone (black star; FAZ; Fig. 2A, B). Microvascular aneu-
risms that are regularly and frequently seen in BM preparations
from diabetic but not in preparations from non-diabetic eyes
(Fig. 2B, red arrow, 2C, white stars) were excluded from the mea-
surements. Results showed that the outer diameter of capillary
tubes from diabetic eyes were consistently thicker than that from
non-diabetic eyes (Fig. 2D). The data were plotted according to age
to account for the slight age-dependent increase in the capillary
Fig. 2. Sheets of retinal vascular BM from a non-diabetic (A) and a diabetic eye (B). The sheets, stained for collagen IV, are from the foveal area with the foveal avascular zone (FAZ)
in the center. Note the presence of microvascular aneurisms at low magniﬁcation (B; red arrow) and at high power (C, white stars). The outer diameter of the capillaries that outline
the FAZ were measured and plotted against age. The plot shows that the diameter of the capillaries from non-diabetic eyes slightly increases with age. The plot also shows that the
diameter of the capillaries from diabetic eyes is approximately 5 mm greater than the diameter of capillaries from non-diabetic eyes when diabetes is longer than 10 years. Bars: A, B:
800 mm; C: 50 mm.
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vascular BM preparations from eyes of type I, type II, insulin-
dependent and non-insulin dependent patients (Fig. 2D). Howev-
er, the duration of the diabetic condition mattered, as capillary
diameter increases were minor with diabetes durations of less than
5 years. The diameter differences between vascular BMs from dia-
betic with a diabetes 10 years and non-diabetic eyes were on
average 5 mm. Since measurements of the capillary tube diameter
from the whole mounts included the two sides of the BM walls we
inferred that the increase in the thickness of an individual vascular
BM wall with 10 years of diabetes relative to non-diabetic eyes is
approximately 2.5 mm.
3.2. Diabetes-related morphological changes of the inner limiting
membrane
The inner limiting membrane (ILM) was the second BM that was
investigated for this study. The ILM is a BM that is located at the
vitreal border of the retina (Fig. 3A, B). Measurements of ILM
thickness by TEM were straightforward and reliable as the angle of
sectioning was perpendicular to the retinal surface and a deﬁned
area of the retina was selected (Candiello et al., 2010). After
examining only a few samples, it became obvious that the thickness
of ILMs from diabetic eyes (Fig. 3A) was much greater than the
thickness of the ILMs from similar aged non-diabetic retinas
(Fig. 3B). Subsequent systematic measurements were based on TEM
imaging of 27 non-diabetic and 11 diabetic retinas. Consistent with
earlier studies (Candiello et al., 2010), data showed a natural, age-
dependent increase in ILM thickness in non-diabetic eyes(Fig. 3C). Further, the ILMs from diabetic eyes were consistently
thicker than the ILM from non-diabetic eyes of similar age (Fig. 3C).
This applied equally to eyes from type I, type II, non-insulin and
insulin-dependent diabetic patients (Fig. 3C). The duration of dia-
betes played, as in the vascular BMs, a major role, as the increase in
ILM thickness was only minor with less than 5 years of diabetes.
TEM imaging of BMs requires chemical ﬁxation and dehydration
of the retinal samples. To determine the thickness of the ILMs under
native conditions, we isolated ILMs from adult human diabetic and
non-diabetic retinas (Fig. 1C) and used atomic force microscopy
(AFM) to measure the thickness of ILMs. Previous TEM examination
showed that the isolated ILMs were free of cellular debris and or-
ganelles (Candiello et al., 2010). For the AFM measurements, the
ILMs were ﬂat-mounted on glass slides with the vitreal side facing
up (Fig. 4A). Thicknessmeasurements were done along the edges of
the ILM sheets or along scratches in the ILM to determine the
height difference between the ILM and the adjacent the glass sur-
face (Fig. 4A, B). AFM-based height measurements of the ﬂat-
mounted ILMs showed that the thickness of non-diabetic ILMs
naturally increased with advancing age, consistent with previous
AFM measurements (Fig. 4C; Candiello et al., 2010) and consistent
with the age-dependent increase in ILM thickness recorded by TEM
(Fig. 3C). Likewise, similar to the TEM-based measurements, the
thickness of ILMs from diabetic eyes was greater than the thickness
of ILMs from similar-aged non-diabetic eyes (Fig. 4C).
When TEM and AFM-based thickness measurements of ILMs
from non-diabetic eyes were compared, the AFM thickness of an
ILM of a given age was approximately twice the TEM-based thick-
ness (Fig. 4D). This difference is due to the large quantities of water
Fig. 3. Diabetic and non-diabetic ILMs. The TEM images in (A) and (B) show representative micrographs of ILMs from a 62-year old diabetic and a 63-year old non-diabetic patient.
The graph in (C) shows that a) the thickness of ILMs increases with age, and b) the thickness of ILMs from diabetics is approximately doubled compared to ILMs from age-matched
non-diabetic eyes. Except for the retinal sample marked by a black star, all samples came from patients with type II diabetes. The duration of diabetes was at least 10 years, except
for the ILM marked by a green star (5 years). IDDM: insulin dependent diabetic; NIDDM: non-insulin dependent diabetic. Bar: A, B: 500 nm.
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that is retained when using the AFM, since our AFMmeasurements
were performed under aqueous conditions (Candiello et al., 2010).
Whenwe compared the AFM and TEMmeasurements of ILMs from
diabetic eyes, we found that the AFM and TEM thickness data were
similar, indicating that the water content of BMs from diabetic eyes
is less than in BMs from non-diabetic BMs and suggests that BMs
from diabetic eyes have a denser ECM and are, therefore, stiffer
than normal (Fig. 4E).
To investigate the biomechanical qualities of ocular BMs, we
compared the stiffness of ﬂat-mounted ILMs from diabetic and
non-diabetic eyes by AFM. Representative force curves from an ILM
of a non-diabetic and a diabetic eye are shown in Fig. 4F. On
average, force curves for ILMs from the diabetic eyes were steeper
(i.e. stiffer ILMs) than the force curves of the ILMs from non-
diabetic eyes suggesting a diabetes-induced increase in BM stiff-
ness. The combined stiffness measurements from six diabetic and
from six non-diabetic eyes are plotted in the summary graph in
Fig. 4G. The graph conﬁrmed that, on average, ILMs from diabetic
eyes are stiffer than ILMs from non-diabetic eyes. The difference in
stiffness varied between 20 and 60%.
3.3. Changes in the protein composition of BMs from diabetic
retinas
Previous studies have shown that the protein composition of
vascular BMs from diabetic eyes partially differs from the protein
composition of vascular BMs from non-diabetic eyes (Ljubimov
et al., 1996; Roy et al., 1996). Major candidates of diabetes-speciﬁc
BM proteins were ﬁbronectin and tenascin (Ljubimov et al., 1996;
Roy et al., 1996). Both proteins are extracellular matrix proteins of
the interstitial connective tissue and are not standard constituents
of normal BMs.
Staining of retinal cross sections of diabetic and non-diabetic
retinas conﬁrmed the abundance of ﬁbronectin in the ILM of dia-
betic eyes and the absence of this protein in the ILM of non-diabetic
retinas (Fig. 5AeC). The abundance of ﬁbronectin in diabetic retinas
was further investigated in ILM whole mounts to localize the
sidedness of ﬁbronectin deposition in the ILM (Fig. 5DeG). Data
showed that ﬁbronectin is localized on the retinal side of the ILM
(Fig. 5D, E) and undetectable in ILMs from non-diabetic eyes
(Fig. 5F). The side-speciﬁc localization was conﬁrmed based on co-localization with side-speciﬁc protein markers, such as laminin,
which is localized on the retinal side and collagen IV 7S a3/4/5,
which is localized on the vitreal side of the ILM (Fig. 5E, G; Halfter
et al., 2013b).
The ILMs from diabetic eyes roll up similar to ILMs from non-
diabetic eyes, whereby the retinal surface is facing outside and
the vitreal side facing inside (Fig. 5H, Halfter et al., 2013b). Double-
labeling of ILMs also showed a side-selective abundance of laminin
on the retinal side and 7S domain of the collagen IV a3/4/5 on the
vitreal side (Fig. 5I, J) in diabetic and non-diabetic eyes, indicating
that the two-layered structure of the ILM from non-diabetic eyes is
not disrupted in the ILMs of diabetic eyes.
Staining of vascular BM whole mounts showed that ﬁbronectin
is abundant in larger vessels and in the microvascular aneurisms of
the retinal capillaries in the diabetic retinas (Fig. 6A, B) and unde-
tectable in the vascular BMs of non-diabetic eyes (Fig. 6C). Micro-
vascular aneurisms are regularly and frequently seen in vascular
BMs in diabetic eyes (Fig. 2B, C) and never observed in non-diabetic
eyes (see Fig. 2A).
Staining of cross section of diabetic and non-diabetic retinas
showed that tenascin is up-regulated in the retinal vascular BMs
(Fig. 6D, H). However, in difference to ﬁbronectin, tenascin was not
detected in the ILM of the diabetic retina (Fig. 6D, H). Staining of
vascular whole mounts showed that tenascin is abundant in larger
retinal vessels and in the microvascular aneurisms of the diabetic
eyes (Fig. 6E). Very little tenascin labeling was detected in vascular
whole mounts of non-diabetic eyes (Fig. 6F). Comparison of the
distribution of ﬁbronectin (Fig. 6G), tenascin (Fig. 6H) and collagen
IV (Fig. 6I) in retinal microvascular aneurisms showed that the bulk
of protein in these aneurisms was collagen IV, and that ﬁbronectin
and tenascin are added prominently as an outer ring to the collagen
IV-dominated BM core.
Changes in the protein composition and relative abundance of
laminin, collagen IV, agrin, ﬁbronectin and tenascin in vascular BMs
was determined by SDS PAGE and western blotting (Fig. 7). SDS
PAGE followed by Coomassie-staining revealed only slight differ-
ences in the protein banding patterns between vascular BMs
samples from non-diabetic and diabetic eyes (Fig. 7, lanes 1, 2). To
compare the relative abundance of speciﬁc proteins by western
blotting, the concentrations of solubilized vascular BM proteins
from diabetic and non-diabetic were normalized. Western blots
stained with polyclonal antisera to laminin (Fig. 7, lanes 3, 4), to
Fig. 4. The thickness of diabetic and non-diabetic ILMs as recorded by Atomic force microscopy (AFM): an AFM-generated image of the edge of an ILM is shown in (A). The ILM had
been ﬂat-mounted on a glass slide. The glass surface served as a reference for height measurements. The red line indicates a trace of the AFM probe to determine the thickness of the
sample. Representative height traces of a diabetic and a non-diabetic ILM is shown in (B). AFM-based thickness measurements of non-diabetic and diabetic ILMs are plotted in (C). It
shows that a) ILMs from non-diabetic eyes increase in thickness with advancing age, and b) that ILMs from diabetic eyes are on average twice thicker than similar aged-non-diabetic
ILMs. When the TEM and AFM thickness data of ILMs from non-diabetic control eyes are compared, the AFM thickness measurements are approximately twice greater than TEM-
based thickness measurements (D). In contrast, AFM and TEM thickness measurements of ILMs from diabetic eyes are similar and less age-dependent (E). This implies that the
diabetes-induced increase in ILM thickness results in a denser, less hydrated BM. This was conﬁrmed by AFM-based stiffness measurements: representative force curves from a
diabetic ILM (DBT; 83 year of age) and a non-diabetic eye (F; non-DBT; 81 years of age) showed a steeper slope for the ILM from the diabetic eye than the force curve for the ILM
from the non-diabetic eye. The summary of all stiffness measurements from six diabetic and six non-diabetic eyes and based on 6000 force curves showed that the stiffness of the
ILMs from diabetic eyes is, on average, greater (37.9  1.2 kPa) than the stiffness of ILMs from non-diabetic eyes (24.3  1.2 kPa).
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monoclonal antibodies to ﬁbronectin (Fig. 7, lanes 11, 12) and
tenascin (Fig. 7, lanes 13, 14) showed that the relative concentra-
tions of laminin and collagen IV in BMs from diabetic and non-
diabetic eyes were similar, whereas the relative abundance of
agrin, ﬁbronectin and tenascin were higher in vascular BMs of
diabetic than in non-diabetic eyes (Fig. 7). Agrin is a proteoglycan
with long glycosaminoglycan side chains and runs as a smear
around 400 kD (Fig. 7, lanes 7, 8). Deglycosylation of the samples
reduced the 400 kD smear to the size of core protein of around200kD (Fig. 7, lanes 9, 10). The western blots showed that both
glycosylated agrin as well as the core protein of agrin are elevated
in concentration in BMs of diabetic eyes (Fig. 7, lanes 7e10).
4. Discussion
4.1. Diabetes-induced changes in the morphology of the ocular BMs
A hallmark of long-term diabetes in the human eye is the
thickening of retinal vascular BMs (Ashton, 1974). In addition to
Fig. 5. Fibronectin is present in the ILMs of diabetic human retinas but not in ILMs from a non-diabetic retinas. Cross sections of human retinas were stained for ﬁbronectin (a-FN;
red; A, B). The section in panel (A) was from a 54-years old insulin-dependent diabetic patient and shows a prominent ﬁbronectin-labeling of the ILM. The section in panels B and C
were from a 66-year-old non-diabetic patient. FN was not detectable in the ILM of the non-diabetic eye (B). Double labeling for collagen IV (green; C) showed the presence of an
intact ILM in this section (C). By staining ILM ﬂat mounts with anti-ﬁbronectin (D, F) or double stained with anti-ﬁbronectin and anti-7S collagen IV (E, G), it was found that the
diabetes-induced ﬁbronectin is located at the retinal side (Ret) and not on the vitreal side (Vit) of the ILM. Anti-laminin staining serves as a marker for the retinal side, whereas anti-
collagen IV 7S a3/4/5 staining serves as a marker labeled for the vitreal side of human ILMs. Isolated ILMs from diabetic eyes roll up like ILMs from non-diabetic eyes (H). The
sidedness of the ILM from diabetic eyes and non-diabetic eyes is preserved as cross sections of retinas from diabetic (I) and from non-diabetic eyes (J) show a prominent laminin
labeling on the retinal side (Ret) and a prominent 7S collagen IV-labeling of the vitreal side (Vit) of the ILMs. Scale Bar: AeC: 50 mm; DeG: 100 mm; I, J: 5 mm.
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retina from the adjacent vitreous, also undergoes a diabetes-
induced thickness increase that is even more substantial than
that of vascular BMs and suggests that BM thickening during dia-
betes is a systemic condition that affects many, if not all, BMs of the
body. As shown previously, the ILM (Candiello et al., 2010), like
many other BMs (Danysh and Duncan, 2008; Danysh et al., 2008;
Murphy et al., 1984; Neuman et al., 2004; Vazquez et al., 1996; Xi
et al., 1982), naturally increases in thickness with progressing age.
Since the thickness increase of BMs during long-term diabetes is on
average doubled as compared to age-matched controls, one is
tempted to speculate that long-term diabetes causes an accelerated
aging with respect to the production of BM extracellular matrix.
Other studies hypothesized that chronic inﬂammation (Gardiner
et al., 2003), a posttranslational glycation of proteins due to high
serum glucose (Degenhardt et al., 1998; King, 2001; Stitt et al., 1997;
Zhang et al., 2009) or an up-regulation of growth factors (Curtis
et al., 2009; Durham and Herman, 2011; Kuiper et al., 2008; Zatzand Brenner, 1986) are the underlying cause for diabetes-related
BM thickening.
As shown for the non-diabetic chick and human eye, the syn-
thesis of ILM proteins is tightly regulated with a high synthesis
during embryogenesis and early postnatal life followed by a dra-
matic down regulationwith little BM protein synthesis during adult
life (Halfter et al., 2005, 2008). The slow but steady increase in BM
thickness during normal life is most likely due to the very long half-
life of BM proteins combined with a continued yet very low rate of
BM protein synthesis. The assumption of a long half-life of BM
proteins is based on the fact that the half-life of collagens in vit-
reous and cartilage ranges between 11 and 100 years (Bishop et al.,
2003; Maroudas et al., 1992; Verzijl et al., 2000, 2001).
Earlier studies showed a diabetes-induced up-regulation of
collagen IV and ﬁbronectin, indicating a switch in the translational
control of BM protein synthesis (Roy et al., 1996). Since the regu-
latory process for BM protein synthesis is altered during diabetes,
BM thickening is likely due to an inﬂammatory/ﬁbrosis condition
Fig. 6. Whole mount staining showing the diabetes-induced abundance of ﬁbronectin and tenascin in vascular BMs of diabetic eyes (A). The staining of retinal vascular BM whole
mounts demonstrates that ﬁbronectin is particularly abundant in larger vessels (A, star) and in the vascular microvascular aneurisms of the retinal capillaries (A, B; arrow). Note,
that ﬁbronectin is all but absent in non-diabetic vascular BMs (C). Staining of retinal cross sections (D) and vascular whole mounts (E) with anti-tenascin showed that the protein
was expressed in retinal vascular BMs of diabetic eyes with a high expression in large vessels (D, E; star) and in microvascular aneurisms (E, arrow) but undetectable in vascular BMs
of non-diabetic eyes (F). Fibronectin (G) and tenascin (H) are particular high in the outer layer of the large vessels in retinas from diabetic eyes, whereas the bulk of the vessel BMs is
provided by collagen IV (I). Bar: A, C: 50 mm; B, D, E, F: 50 mm. GeI: 50 mm.
M. To et al. / Experimental Eye Research 116 (2013) 298e307 305with excessive production of BM protein, possibly following a
cytokine-induced up-regulation of growth factors, such as TGFb,
FGF-2 and CTF (Kuiper et al., 2008). What is currently unknown is
whether the increase in BM thickness is mainly due to an elevated
synthesis and deposition of the standard BM proteins, such as
collagen IV and laminin, or due to the synthesis and deposition of
diabetes-speciﬁc proteins that are normally not present in BMs.
There are several ﬁndings arguing that BMs, at least in part, un-
dergo a change in their protein composition during long-term
diabetes.
4.2. Diabetes-induced compositional changes of BMs
The increase in ILM thickness, as detected by light and trans-
mission electron microscopy, was conﬁrmed by AFM, a highresolution imaging and probingmethod that allows investigation of
unﬁxed and fully hydrated samples. Consistent with earlier AFM
data, we found that the thickness of adult human and embryonic
chick ILMs, whenmeasured by AFM, was at least twice greater than
measured by TEM. The sample preparation for TEM requires
dehydration that normally leads to shrinkage of tissues between 10
and 20%. However, the over 50% difference of AFM and TEM
thickness measurements indicated that BMs contain a much
greater amount of water than other tissues (Balasubramani et al.,
2010; Candiello et al., 2010). BM proteoglycans, such as perlecan,
agrin and collagen XVIII that are present in BMs, are the prime
candidates for the water-binding constituents in BMs. Earlier ex-
periments showed that when the GAG chains of ILM samples in
human and chick ILM were enzymatically removed, the ILMs un-
derwent a 50% shrinkage (Balasubramani et al., 2010; Candiello
Fig. 7. Western blots comparing the protein-banding patterns and the abundance of
laminin (LN), collagen IV (ColIV), agrin (Ag), ﬁbronectin (FN) and tenascin (TN) in non-
diabetic control (Co) and diabetic (Di) retinal vascular BMs. Vascular BMs from a non-
diabetic control and a similar aged (72 year) diabetic retina were loaded for SDS PAGE.
The samples had been normalized for identical protein concentrations. The protein
banding patterns were detected by Coomassie blue staining (Coom, lanes 1, 2)) of the
gel, and it showed a slightly different banding for diabetic versus non-diabetic BMs.
Western blots were stained with antibodies to laminin (a-Ln, lanes 3, 4), collagen IV (a-
ColIV, lanes 5, 6, agrin (a-Ag, lanes 7e10), ﬁbronectin (a-FN, lanes 11, 12) and tenascin
(a-TN, lanes 13, 14). While the relative abundance of laminin, and collagen IV was
similar in non-diabetic and diabetic BMs, agrin, ﬁbronectin and tenascin were more
abundant in the diabetic BMs. For the detection of agrin, samples were loaded without
deglycosylation of the BMs (lanes 7, 8) or after deglycosylation of the BMs (lanes 9, 10).
M. To et al. / Experimental Eye Research 116 (2013) 298e307306et al., 2010), demonstrating that water is the most prominent
component of BMs and that this water is retained by the GAG side
chains of proteoglycans. The ﬁnding that the difference of ILM
thickness based on AFM measurements in diabetic eyes is minor,
indicates a lower degree of hydration of the BMs following a loss of
GAG side chains of the proteoglycans. It is conceivable that a lower
hydration and higher compaction of BMs in diabetic vessels has
physiological consequences, including a lower rate of diffusion and
ﬁltration through BMs, a loss of vascular elasticity that may
contribute to chronic high blood pressure, and a higher incidence of
aneurisms and rupture. Western blots showed a higher agrin con-
centration in diabetic as compared to non-diabetic retinal blood
vessels. That appears to be in contrast to the lower water content
that the AFM data suggest. Previous studies in chick ILM (Halfter
et al., 2005) have shown that the GAG side chains for collagen
XVIII decrease in length with advancing age, and we propose that
the loss of glycosylation for collagen XVIII or perlecan could be
responsible for the loss of water storage in diabetic BMs. Consistent
with the current thickness data and consistent with our assump-
tion of a higher compaction of BMs in diabetes patients, AFM
studies showed that the ILMs from diabetic eyes are stiffer than
ILMs from non-diabetic eyes. We propose that the higher density of
protein and the lower hydration renders diabetic BMs more brittle
and more prone to breaks. Indeed, isolating the Descemet’s mem-
brane from corneas of diabetic patients is complicated by the fact
that the BMs break into small pieces, whereas the Descemet’s
membrane from non-diabetic patients can be regularly peeled off
in one piece (W.H. personal observation).
Consistent with earlier studies (Ljubimov et al., 1996; Roy and
Lorenzi, 1996), we found that ﬁbronectin and tenascin, both of
which are normally absent in the retinal BMs, are expressed in
diabetic vascular BMs. The data also show that the diabetes-
induced ﬁbronectin is localized at the side of the ILM that faces
the retinal neuroepithelium.We hypothesize that the ﬁbronectin in
the ILM of diabetic eyes originates from the Muller glia cells that
have been shown to undergo a diabetes-induced activation (Coorey
et al., 2012). Fibronectin and tenascin are considered typicalinterstitial extracellular matrix components and not standard BM
proteins. Both proteins are up-regulated during wound healing
(Pankov and Yamada, 2002; Mackie et al., 1988) and in the con-
nective tissues surrounding tumors (Chiquet-Ehrismann and
Tucker, 2004). Studies have shown that a variety of growth fac-
tors lead to a massive over-expression of both proteins (Caligliero
et al., 1988; Chiquet-Ehrismann and Tucker, 2004), and the strong
up-regulation of ﬁbronectin and tenascin in diabetes argues in
favor of a chronic and sustained inﬂammatory process that affects
the cells that participate in the synthesis of BM proteins. Our
vascular BM whole mount preparations revealed that both ﬁbro-
nectin and tenascin were particularly abundant in the microvas-
cular aneurisms, indicating a focal up-regulation of both proteins at
speciﬁc sites of the retinal vasculature. It as been well documented
that long-term diabetes leads to the disappearance of pericytes and
one is tempted to hypothesize that the vascular herniation are sites
where pericytes might have died. However, the fact that BM
thickening also affects the ILM, which is not in contact with peri-
cytes, argues against a connection of BM thickening and pericyte
loss. It is also possible that the aneurisms are sites of de-novo
angiogenesis sprouts combined with a focal change in the protein
composition, leading to a biomechanically altered, possibly weaker,
segment in the vascular BM tubes.
Our studies also showed that agrin, both in the glycosylated
form as well as the core protein, is more abundant in diabetic as
compared to normal BMs of retinal vascular BMs, whereas the
relative abundance of collagen IV and laminin, the dominant pro-
teins of adult human BMs, was unchanged.
The current data indicate that long-term diabetes lead to a
massive increase in the thickness of BMs possibly due to a chronic
inﬂammation/ﬁbrosis process that affects particularly the synthesis
of BM proteins. We propose that this chronic condition is systemic
and leads to the thickening and stiffening of possibly all BMs of the
body. In addition to an up-regulation of dominant BM protein, such
as collagen IV and agrin, diabetes also leads to the synthesis of
proteins that are not normally present in BM, including ﬁbronectin
and tenascin. The deposition of diabetes-speciﬁc proteins may lead
to the altered morphological and biomechanical changes of BMs
andmay contribute to the various pathologies in long-term diabetic
patients.
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